Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2000
09/14/2000WO2000053176A1 Pharmaceutic, dietetic and cosmetic compositions based on thioctic acid and cysteine
09/14/2000WO2000053175A1 Compounds and methods
09/14/2000WO2000053174A1 Modulation of protein expression using carbocyclic aryl alkenoic acid derivatives
09/14/2000WO2000053173A1 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
09/14/2000WO2000053171A1 Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
09/14/2000WO2000053170A1 Means for diagnosing and treating carcinoma
09/14/2000WO2000053169A2 Method of inhibiting a chaperone protein
09/14/2000WO2000053168A2 Synergy between low molecular weight heparin and platelet aggregation inhibitors, for preventing and treating thromboembolic disorders
09/14/2000WO2000053167A2 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
09/14/2000WO2000053166A2 Use of condensed 2,3-benzodiazepine derivatives for the treatment and prophylaxis of diseases related to the inhibition of lipid peroxidation
09/14/2000WO2000053165A2 Use of inhibitors of endotoxin for the treatment of chachexia
09/14/2000WO2000053162A1 Controlled-release compositions of betahistine
09/14/2000WO2000053157A1 Improved powdery pharmaceutical compositions for inhalation
09/14/2000WO2000053149A2 Method and composition for administering a cyclooxygenase-2 inhibitor
09/14/2000WO2000053148A2 Methods and compositions for treating erectile dysfunction
09/14/2000WO2000053034A1 Active oxygen annihilating agent
09/14/2000WO2000053013A1 Inhibition of pkc to treat permeability failure
09/14/2000WO2000044722A8 Chondrongenesis promotors and indolin-2-one derivatives
09/14/2000WO2000037685A3 Method of identifying a psychotropic agent using differential gene expression
09/14/2000WO2000037469A3 Process for preparing n6-substituted deaza-adenosine derivatives
09/14/2000WO2000037422A3 Ion channel modulating agents
09/14/2000WO2000037110A3 Ribavirin-pegylated interferon alfa induction hcv combination therapy
09/14/2000WO2000037109A3 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions
09/14/2000WO2000037068B1 Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways
09/14/2000WO2000037065A3 Endocrine therapy for breast cancer: combined treatment with tamoxifen plus alkyl pcdfs
09/14/2000WO2000037024A3 Use of water-soluble/dispersible reactive derivatives of polyimido compounds for modifying proteinaceous substrates
09/14/2000WO2000035469A3 hCG THERAPY FOR THE TREATMENT OF BREAST CANCER
09/14/2000WO2000035430A3 Homer a new target of treating psychiatric disorders
09/14/2000WO2000031074A3 Indole derivatives and their use as serotonin receptor ligands
09/14/2000WO2000030587A3 NF-λB ACTIVATION INHIBITORS, AND THEIR PHARMACEUTICAL USES
09/14/2000WO2000030425A3 Method of using pon-1 to decrease atheroma formation
09/14/2000WO2000027376A3 Use of thiol compounds, oxidoreductases and/or hydrolases for the treatment of tinnitus, especially chronic tinnitus
09/14/2000WO2000024717A3 Isoquinoline derivatives
09/14/2000WO2000023599A3 Human proteins involved in endoplasmic reticulum protein degradation
09/14/2000WO2000023588B1 G-protein coupled receptors
09/14/2000WO2000023568A3 Methods and compositions for decreasing mitochondrial overproduction of reactive oxygen species in cells
09/14/2000WO2000023071A9 Pharmaceutical formulations useful to treat inflammatory and immune disorders
09/14/2000WO2000019964A3 Novel compositions and methods for prevention and treatment of protozoal disease
09/14/2000WO2000018232A9 Method of treatment of cardiovascular injuries
09/14/2000WO2000016753A3 Use of nucleosides, nucleobases and their derivatives for reducing the thrombocytopenic side effects of cytostatic agents
09/14/2000WO2000013709A3 Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
09/14/2000WO2000004012A8 COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
09/14/2000WO2000003978A3 2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same
09/14/2000WO1999066875A3 Combined preparation of anti-infectiously active compounds which inhibit the 2-c-methylerythrose-4 metabolic pathway, and inhibitors of lipid metabolism
09/14/2000WO1999065228A3 Pharmaceutical combination used to compensate for a testosterone deficiency while protecting the prostate
09/14/2000WO1999063999A8 H1-histamine receptor antagonists
09/14/2000WO1999062876A8 24,24-difluorinated analogs of 1-alpha,25-dihydroxy vitamin d3
09/14/2000WO1999033836A9 3'-epimeric k-252a derivatives
09/14/2000DE19911097A1 Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen A process for the preparation of solid dosage forms cyclodextrin
09/14/2000DE19911064A1 Dosieraerosole mit Isobutan als Treibmittel MDIs containing isobutane as a propellant
09/14/2000DE19911039A1 Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung Modified amino acid amides, pharmaceutical compositions containing them and methods for their preparation
09/14/2000DE19910370A1 Verfahren zur Herstellung von Tensidalkoholen und Tensidalkoholethern, die hergestellten Produkte und ihre Verwendung A process for the preparation of surfactant alcohols and surfactant alcohol ethers, the manufactured products and their use
09/14/2000DE19908787A1 Transdermal therapeutic system for administration of fenoterol and formoterol, useful for treating obstructive respiratory disorders
09/14/2000CA2478736A1 Compositions and methods for the treatment of tumors
09/14/2000CA2478730A1 Compositions and methods for the treatment of tumors
09/14/2000CA2478728A1 Compositions and methods for the treatment of tumors
09/14/2000CA2371927A1 Nitric oxide manipulation of muscle satellite cell activation
09/14/2000CA2367334A1 Compositions and methods for the treatment of tumors
09/14/2000CA2367130A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2367126A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2367113A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2367108A1 Method of inhibiting a chaperone protein
09/14/2000CA2366719A1 Solubilization of polyunsaturated fatty acids and their derivatives by formation of inclusion complexes with y-cyclodextrin and their use in pharmaceutical, cosmetic or food compositions
09/14/2000CA2366675A1 L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them
09/14/2000CA2366668A1 Pyrimidine compounds
09/14/2000CA2366644A1 Tyrosine kinase inhibitors
09/14/2000CA2366642A1 Carbamoyl tetrahydropyridine derivatives
09/14/2000CA2366632A1 Method for producing glyco-conjugates of 20(s)-camptothecin
09/14/2000CA2366615A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone
09/14/2000CA2366609A1 4-oxo-4,7-dihydro-thieno¬2,3-b|pyridine-5-carboxamides as antiviral agents
09/14/2000CA2366607A1 Thiazolyl urea derivatives and their utilization as antiviral agents
09/14/2000CA2366602A1 Pyridoxal analogues for vitamin b-6 disorders
09/14/2000CA2366308A1 Inhibitors of protein tyrosine phosphatase
09/14/2000CA2366281A1 Novel ligands of nuclear receptors ppar's
09/14/2000CA2366087A1 Sialic acid-binding ig-like lectin (siglec) gene; ob-binding protein like (ob-bpl)
09/14/2000CA2365869A1 Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
09/14/2000CA2364470A1 Medicament against dysmenorrhoea and premenstrual syndrome
09/14/2000CA2364449A1 Anti-hiv agent
09/14/2000CA2364257A1 Liposome preparations
09/14/2000CA2364253A1 Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
09/14/2000CA2364252A1 Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders
09/14/2000CA2364226A1 Controlled-release compositions of betahistine
09/14/2000CA2363590A1 Method and composition for administering a cyclooxygenase-2 inhibitor
09/14/2000CA2363255A1 Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
09/14/2000CA2362918A1 Methods and compositions for treating erectile dysfunction
09/14/2000CA2362885A1 Human kallikrein-like genes
09/14/2000CA2362319A1 Imidazole compounds as histamine h3 ligands
09/14/2000CA2361849A1 Promotion or inhibition of angiogenesis and cardiovascularization
09/14/2000CA2361650A1 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
09/14/2000CA2359485A1 Analgesic compositions comprising anti-epileptic compounds and methods of using same
09/14/2000CA2359218A1 14.beta., 17-alpha-hydroxymethylandrostane derivatives as androgens
09/13/2000EP1035127A1 Process for the preparation of N-[5-(Diphenylphosphinoylmethyl)-4-(4-fluorphenyl)-6-isopropylpyrimidin-2-yl]-N-methylmethansulfonamide
09/13/2000EP1035115A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
09/13/2000EP1035110A1 Benzylaminodiacetamide derivatives, compositions containing the same, process for their preparation and uses
09/13/2000EP1034794A1 A formulation of dihydroartemisinin for the control of wide spectrum of malaria
09/13/2000EP1034793A1 Preventives/remedies for glaucoma
09/13/2000EP1034785A2 Hepatitis C virus diagnostics and vaccines
09/13/2000EP1034784A2 Pharmaceutical formulations containing clavulanic acid and an antibacterial agent
09/13/2000EP1034782A1 Treatment of depression by using compounds which elevate the intracellular sodium concentration
09/13/2000EP1034780A2 Betamethasone- and hyaluronic acid-treated thin adhesive plaster for the treatment of psoriasis, dermatitis and dermatosis
1 ... 6246 6247 6248 6249 6250 6251 6252 6253 6254 6255 6256 6257 6258 6259 6260 6261 6262 6263 6264 6265 6266 ... 7860